logo-loader
Lipocine Inc

Lipocine's LPCN 1111 Phase 2b clinical study kicks off

The first patient has been dosed in Lipocene's Phase 2b clinical study for LPCN 1111, its novel testosterone replacement therapy product candidate.

Testosterone.jpg
LPCN 1111 is a follow-on product candidate to LPCN 1021

The first patient has been dosed in Lipocene's (NASDAQ:LPCN) Phase 2b clinical study for LPCN 1111, its novel testosterone replacement therapy product candidate.

The market did not seem pumped up by the news, as the shares shed 3.9% at US$12.42 in early trading.

The primary objectives of the study will be to determine the optimal dose of LPCN 1111, along with the safety and tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses of LPCN 1111 in males suffering a diminished functional activity of the gonads.

"Progress with this product builds on our leadership position in oral testosterone replacement therapy," said Dr Mahesh Patel, president and chief executive officer of Lipocine.

LPCN 1111 is a follow-on product candidate to LPCN 1021, a twice-daily oral testosterone product candidate that is currently under regulatory review with a Food & Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date of June 28, 2016.

 

Quick facts: Lipocine Inc

Price: $2.34

Market: NASDAQ
Market Cap: $58.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

2 days, 4 hours ago

2 min read